Literature DB >> 15190388

Role of dopamine D3 receptors in the addictive properties of ethanol.

Christian A Heidbreder1, Michela Andreoli, Clara Marcon, Panayotis K Thanos, Charles R Ashby, Eliot L Gardner.   

Abstract

After the cloning of the dopamine D(1) and D(2) receptors (1-3), several additional dopamine receptors were identified. These new subtypes included the D(3) and D(4) receptors, which are similar to D(2), and the D(5) receptor, which is similar to D(1) (4-6). Although most studies have focused on the role of dopamine D(1) and D(2) receptors in mediating the addictive liability of drugs, the lack of selective pharmacological tools has significantly hampered this particular field of research. In contrast, recent studies using selective competitive antagonists have shown that the dopamine D(3) receptor is involved in drug-seeking behavior. The present review is intended to highlight a new, promising area in alcohol research that focuses on the role of the dopamine D(3) receptor in the addictive properties of ethanol. (c) 2004 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15190388     DOI: 10.1358/dot.2004.40.4.820081

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  9 in total

1.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

Review 2.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

Review 3.  [Future medications for tobacco and cannabis dependence].

Authors:  Bernard Le Foll; Zuzana Justinova; Gianlugi Tanda; Steven R Goldberg
Journal:  Bull Acad Natl Med       Date:  2008-01       Impact factor: 0.144

Review 4.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

5.  Decreased dopamine D(2) receptor function in cerebral cortex and brain stem: their role in hepatic ALDH regulation in ethanol treated rats.

Authors:  Akash K George; S Balarama Kaimal; C S Paulose
Journal:  Mol Cell Biochem       Date:  2007-05-26       Impact factor: 3.396

6.  Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups.

Authors:  Donald M N Sikazwe; Nancy T Nkansah; Ramazan Altundas; Xue Y Zhu; Bryan L Roth; Vincent Setola; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2008-12-31       Impact factor: 3.641

7.  Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.

Authors:  Thomas M Keck; William S John; Paul W Czoty; Michael A Nader; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-03-31       Impact factor: 7.446

8.  High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice.

Authors:  Comfort A Boateng; Oluyomi M Bakare; Jia Zhan; Ashwini K Banala; Caitlin Burzynski; Elie Pommier; Thomas M Keck; Prashant Donthamsetti; Jonathan A Javitch; Rana Rais; Barbara S Slusher; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-07-23       Impact factor: 7.446

9.  Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?

Authors:  Marjorie C Gondré-Lewis; Igor Elman; Tanya Alim; Edwin Chapman; Beverlyn Settles-Reaves; Carine Galvao; Mark S Gold; David Baron; Shan Kazmi; Eliot Gardner; Ashim Gupta; Catherine Dennen; Kenneth Blum
Journal:  Biomedicines       Date:  2022-04-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.